Raymond James & Associates Trims Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Raymond James & Associates lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) by 12.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,463 shares of the specialty pharmaceutical company’s stock after selling 3,481 shares during the period. Raymond James & Associates’ holdings in Jazz Pharmaceuticals were worth $3,394,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Gladius Capital Management LP purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter worth $33,000. Fifth Third Bancorp raised its stake in shares of Jazz Pharmaceuticals by 32.9% during the 2nd quarter. Fifth Third Bancorp now owns 279 shares of the specialty pharmaceutical company’s stock valued at $44,000 after purchasing an additional 69 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Jazz Pharmaceuticals during the 3rd quarter valued at about $78,000. SJS Investment Consulting Inc. bought a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at about $101,000. Finally, Brown Brothers Harriman & Co. purchased a new stake in shares of Jazz Pharmaceuticals in the first quarter worth about $101,000. 89.79% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on JAZZ. Royal Bank of Canada upped their target price on shares of Jazz Pharmaceuticals from $206.00 to $207.00 and gave the stock an “outperform” rating in a report on Thursday, November 10th. The Goldman Sachs Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $192.00 to $190.00 in a research report on Thursday, December 8th. Needham & Company LLC reduced their target price on Jazz Pharmaceuticals from $210.00 to $208.00 and set a “buy” rating for the company in a research report on Thursday, November 10th. Finally, StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 21st. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $202.33.

Jazz Pharmaceuticals Trading Up 0.8 %

Shares of JAZZ stock opened at $156.12 on Friday. The business has a 50-day moving average of $154.32 and a 200 day moving average of $150.14. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.16 and a quick ratio of 2.27. Jazz Pharmaceuticals plc has a 1-year low of $125.36 and a 1-year high of $169.98. The stock has a market capitalization of $9.83 billion, a PE ratio of -520.40, a P/E/G ratio of 0.89 and a beta of 0.74.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last released its quarterly earnings data on Wednesday, November 9th. The specialty pharmaceutical company reported $4.53 earnings per share for the quarter, beating analysts’ consensus estimates of $4.35 by $0.18. Jazz Pharmaceuticals had a positive return on equity of 30.71% and a negative net margin of 0.52%. The firm had revenue of $940.65 million during the quarter, compared to analyst estimates of $939.88 million. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 15.24 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $150.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now directly owns 372,028 shares in the company, valued at $55,804,200. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $150.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now owns 372,028 shares of the company’s stock, valued at approximately $55,804,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Samantha Pearce sold 531 shares of the business’s stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $159.59, for a total value of $84,742.29. Following the transaction, the senior vice president now directly owns 11,309 shares in the company, valued at $1,804,803.31. The disclosure for this sale can be found here. Insiders have sold a total of 18,258 shares of company stock valued at $2,817,148 in the last quarter. Insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Company Profile

(Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Featured Stories

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.